Резистентность к терапии препаратами ацетилсалициловой кислоты: факторы риска, механизмы, методы диагностики

Резистентность к терапии препаратами ацетилсалициловой кислоты: факторы риска, механизмы, методы диагностики

Автор: Лукьянец К.Ю., Пчелин И.Ю.

Журнал: Juvenis scientia @jscientia

Рубрика: Обзорные статьи

Статья в выпуске: 2 т.6, 2020 года.

Бесплатный доступ

Ацетилсалициловая кислота (аспирин) является самым распространённым препаратом, используемым для вторичной профилактики атеротромботических событий при сердечно-сосудистых заболеваниях. Соответственно, проблему эффективности терапии аспирином следует считать одной из центральных в кардиологии. Остаётся актуальным вопрос персонализации антиагрегантной терапии, поскольку убедительные данные в пользу применения аспирина с целью первичной профилактики в общей популяции отсутствуют. В настоящем обзоре проанализированы данные последних лет о проблеме резистентности к аспирину. Обсуждаются потенциальные механизмы невосприимчивости к аспирину, возможное влияние генетических факторов на клиническую эффективность антиагрегантной терапии, вопросы стандартизации методов и критериев диагностики резистентности к аспирину, а также возможности её преодоления. Проанализированы данные о клиническом и прогностическом значении 11-дегидротромбоксана В2 как одного из наиболее перспективных маркеров тромбоксан-зависимой активации тромбоцитов.

Еще

Ацетилсалициловая кислота, аспирин, резистентность к аспирину, тромбоциты, антиагреганты, 11-дегидротромбоксан в2, 11-dehydrothromboxane в2

Короткий адрес: https://sciup.org/14115954

IDR: 14115954

Список литературы Резистентность к терапии препаратами ацетилсалициловой кислоты: факторы риска, механизмы, методы диагностики

  • Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860. DOI: 10.1016/S0140-6736(09)60503-1
  • Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046. DOI: 10.1016/S0140-6736(18)31924-X
  • Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. DOI: 10.1136/bmj.324.7329.71
  • Christiansen M, Grove EL, Hvas AM. Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis. Semin Thromb Hemost. 2019;45(5):478-489. DOI: 10.1055/s-0039-1687905
  • Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14):1650-1655. DOI: 10.1161/01.CIR.0000013777.21160.07
  • Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10):1206-1218.
  • DOI: 10.1161/01.cir.101.10.1206
  • Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606-617.
  • DOI: 10.1016/s0140-6736(06)68040-9
  • Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov. 2003; 2:15-28.
  • DOI: 10.1038/nrd985
  • Weber AA, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002;13(1):37-40.
  • DOI: 10.1080/09537100120104890
  • Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141(1):69-78.
  • DOI: 10.1016/j.pharmthera.2013.08.005
  • Schwartz KA. Aspirin resistance: a clinical review focused on the most common cause, noncompliance. Neurohospitalist. 2011;1(2):94-103.
  • DOI: 10.1177/1941875210395776
  • Hally KE, La Flamme AC, Larsen PD, Harding SA. Platelet Toll-like receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction. Thromb Res. 2017;158:8-15.
  • DOI: 10.1016/j.thromres.2017.07.031
  • Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis. 2002;14(1):51-58. DOI: 10.1023/a:1022066305399.
  • O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation. 2001;103(25):3051-3056.
  • DOI: 10.1161/01.cir.103.25.3051
  • Li Q, Chen BL, Ozdemir V, et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007;8(6):577-586.
  • DOI: 10.2217/14622416.8.6.577
  • Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66(2):222-232.
  • DOI: 10.1111/j.1365-2125.2008.03183.x
  • Würtz M, Kristensen SD, Hvas AM, et al. Pharmacogenetics of the antiplatelet effect of aspirin. Curr Pharm Des. 2012;18(33):5294-5308.
  • DOI: 10.2174/138161212803251907
  • Weng Z, Li X, Li Y, et al. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One. 2013;8(11):e78093.
  • DOI: 10.1371/journal.pone.0078093
  • Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011;4(5):605-621.
  • DOI: 10.1586/ecp.11.36
  • Gengo FM, Rubin L, Robson M, et al. Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. J Clin Pharmacol. 2008;48: 117-122.
  • DOI: 10.1177/0091270007310379
  • Greig GM, Francis DA, Falgueyret JP, et al. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol Pharmacol. 1997;52(5):829-838.
  • DOI: 10.1124/mol.52.5.829
  • Angiolillo DJ, Weisman SM. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs. 2017;17(2):97-107.
  • DOI: 10.1007/s40256-016-0200-5
  • Elliott MA. The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains. J Am Coll Cardiol. 2018; 71(16):1752-1754
  • DOI: 10.1016/j.jacc.2018.02.034
  • Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacol. 2009;17:275-342
  • DOI: 10.1007/s10787-009-0016-x
  • MacDonald TM, Wei L. Is there an Interaction between the Cardiovascular Protective Effects of Low-Dose Aspirin and Ibuprofen? Basic Clin Pharmacol Toxicol. 2006;98:275-280.
  • DOI: 10.1111/j.1742-7843.2006.pto_371.x
  • Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-17.
  • DOI: 10.1056/NEJMoa003199
  • Poorani R, Bhatt AN, Dwarakanath BS, et al. COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance. Eur J Pharmacol. 2016;785:116-132.
  • DOI: 10.1016/j.ejphar.2015.08.049
  • Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
  • DOI: 10.1136/bmj.d2690
  • Giraud MN, Sanduja SK, Felder TB, et al. Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther. 1997;11:899-906.
  • DOI: 10.1046/j.1365-2036.1997.00216.x
  • Bhatt DL, Grosser T, Dong JF, et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69(6):603-612.
  • DOI: 10.1016/j.jacc.2016.11.050
  • Haastrup PF, Grønlykke T, Jarbøl DE. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Basic Clin Pharmacol Toxicol. 2015;116(3):212-215.
  • DOI: 10.1111/bcpt.12362
  • Cox D, Fitzgerald DJ. Lack of Bioequivalence Among Low-dose, Enteric-coated Aspirin Preparations. Clin. Pharmacol Ther. 2018;103(6):1047-1051.
  • DOI: 10.1002/cpt.874
  • Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121.
  • DOI: 10.1186/s12933-018-0763-3
  • Ferretti G, Rabini RA, Bacchetti T, et al. Glycated low-density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab. 2002;87:2180-4.
  • DOI: 10.1210/jcem.87.5.8466
  • Simeone P, Boccatonda A, Liani R, Santilli F. Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis. Ageing Res Rev. 2018;48:51-78.
  • DOI: 10.1016/j.arr.2018.09.004
  • Knebel SM, Sprague RS, Stephenson AH. Prostacyclin receptor expression on platelets of humans with type 2 diabetes is inversely correlated with hemoglobin A1c levels. Prostaglandins Other Lipid Mediat. 2015;116-117:131-135.
  • DOI: 10.1016/j.prostaglandins.2014.12.002
  • Koch KL, Calles-Escandón J. Diabetic Gastroparesis. Gastroenterol Clin North Am. 2015;44(1):39-57.
  • DOI: 10.1016/j.gtc.2014.11.005
  • Vanormelingen C, Tack J, Andrews CN. Diabetic gastroparesis. Br Med Bull. 2013;105:213-230.
  • DOI: 10.1093/bmb/ldt003
  • Patrono C, Rocca B. Measurement of Thromboxane Biosynthesis in Health and Disease. Front Pharmacol. 2019;10:1244.
  • DOI: 10.3389/fphar.2019.01244
  • Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672-1686f.
  • DOI: 10.1093/eurheartj/ehy066
  • Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387-399.
  • DOI: 10.1016/S0140-6736(18)31133-4
  • Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121 (10):1701-1711.
  • DOI: 10.1182/blood-2012-10-429134
  • Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2):102-108.
  • DOI: 10.1002/ajh.21338
  • Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595-3603.
  • DOI: 10.1182/blood-2011-06-359224
  • Lordkipanidzé M. Platelet Function Tests. Semin Thromb Hemost. 2016;42(03):258-267.
  • DOI: 10.1055/s-0035-1564834
  • Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105 Suppl 1:S13-S33
  • DOI: 10.1160/THS10-11-0720
  • McFadyen JD, Kaplan ZS. Platelets are not just for clots. Transfus Med Rev. 2015;29(2):110-119
  • DOI: 10.1016/j.tmrv.2014.11.006
  • Hvas AM, Grove EL. Platelet Function Tests: Preanalytical Variables, Clinical Utility, Advantages, and Disadvantages. Methods Mol Biol. 2017;1646:305-320
  • DOI: 10.1007/978-1-4939-7196-1_24
  • Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-3384
  • DOI: 10.1172/JCI27196
  • Roberts LJ 2nd, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem. 1981;256(16):8384-93. PMID:
  • ISBN: 7263660
  • Olson MT, Kickler TS, Lawson JA, et al. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. J Thromb Haemost. 2012;10(12):2462-2469.
  • DOI: 10.1111/jth.12026
  • Geske FJ, Guyer KE, Ens G. AspirinWorks: a new immunologic diagnostic test for monitoring aspirin effect. Mol Diagn Ther. 2008;12(1):51-54.
  • DOI: 10.1007/BF03256268
  • Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118(17):1705-1712.
  • DOI: 10.1161/CIRCULATIONAHA.108.768283
  • Becker DM, Segal J, Vaidya D, et al. Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy. JAMA. 2006;295(12):1420-1427.
  • DOI: 10.1001/jama.295.12.1420
  • Davì G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288(16):2008-2014.
  • DOI: 10.1001/jama.288.16.2008
  • Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006;48(12):2531-2538.
  • DOI: 10.1016/j.jacc.2006.08.040
  • Ferroni P, Basili S, Santilli F, Davì G. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol Haemost Thromb. 2006;35(3-4):346-354.
  • DOI: 10.1159/000093226
  • Notarbartolo A, Davì G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15(2):247-251.
  • DOI: 10.1161/01.atv.15.2.247
  • Dragani A, Falco A, Santilli F, et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. Thromb. Haemost 2012;108(09):533-542.
  • DOI: 10.1160/th11-12-0899
  • Di Minno MN, Pezzullo S, Palmieri V, et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. Thromb Res. 2011;128(4):e43-e48.
  • DOI: 10.1016/j.thromres.2011.05.017
  • Abhinand PA, Manikandan M, Mahalakshmi R, Ragunath PK. Meta-analysis study to evaluate the association of MTHFR C677T polymorphism with risk of ischemic stroke. Bioinformation. 2017;13(6):214-219.
  • DOI: 10.6026/97320630013214
  • De Franchis R, Fermo I, Mazzola G, et al. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost. 2000;84(4):576-82. PMID:
  • ISBN: 11057853
  • Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T Polymorphism and Risk of Coronary Heart Disease: A Meta-analysis. JAMA. 2002;288(16):2023-2031.
  • DOI: 10.1001/jama.288.16.2023
  • Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2(8):1282-1291.
  • DOI: 10.1111/j.1538-7836.2004.00836.x
  • Ha H, Lee HB. Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep. 2001;1(3):282-287.
  • DOI: 10.1007/s11892-001-0047-1
  • Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99(2):224-229.
  • DOI: 10.1161/01.cir.99.2.224
  • De Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014;130(13):1110-1130.
  • DOI: 10.1161/CIR.0000000000000034
  • Zaccardi F, Rizzi A, Petrucci G, et al. In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. Diabetes. 2016;65(2):503-509.
  • DOI: 10.2337/db15-0936
  • Santilli F, Zaccardi F, Liani R, et al. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. Diabetes Metab Res Rev. 2020;36(2):e3232.
  • DOI: 10.1002/dmrr.3232
  • Dołegowska B, Błogowski W, Kedzierska K, et al. Platelets arachidonic acid metabolism in patients with essential hypertension. Platelets. 2009;20(4):242-249.
  • DOI: 10.1080/09537100902849836
  • Minuz P, Patrignani P, Gaino S, et al. Determinants of platelet activation in human essential hypertension. hypertension. 2004;43(1):64-70.
  • DOI: 10.1161/01.HYP.0000105109.44620.1B
  • Guagnano MT, Ferroni P, Santilli F, et al. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic Biol Med. 2009;46(7):922-927.
  • DOI: 10.1016/j.freeradbiomed.2009.01.005
  • Barua RS, Sharma M, Dileepan KN. Cigarette Smoke Amplifies Inflammatory Response and Atherosclerosis Progression Through Activation of the H1R-TLR2/4-COX2 Axis. Front Immunol. 2015;6:572.
  • DOI: 10.3389/fimmu.2015.00572
  • Barbieri SS, Zacchi E, Amadio P, et al. Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction. Cardiovascular Research. 2011;90(3),475-483.
  • DOI: 10.1093/cvr/cvr032
  • Barbieri SS, Weksler BB. Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J. 2007;21(8):1831-1843.
  • DOI: 10.1096/fj.06-7557com
  • Lowe FJ, Gregg EO, McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med. 2009;47(3):311-320.
  • DOI: 10.1515/cclm.2009.069
  • Oliveri D, Liang Q, Sarkar M. Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm between Adult E-Vapor Users and Adult Cigarette Smokers. Nicotine Tob Res. 2019;ntz185.
  • DOI: 10.1093/ntr/ntz185
  • Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7(12):662.
  • DOI: 10.1038/s41408-017-0035-6
  • Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-761.
  • DOI: 10.1016/j.amjmed.2004.06.032
  • Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857-5859.
  • DOI: 10.1182/blood-2011-02-339002
  • Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232.
  • DOI: 10.1200/JCO.2005.07.062
  • Ferrante E, Vazzana N, Santilli F, et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. Free Radic Biol Med. 2010;49(5):857-864.
  • DOI: 10.1016/j.freeradbiomed.2010.06.009
  • Ferro D, Basili S, Roccaforte S, et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthritis Rheum. 1999;42(12):2689-2697. :123.0.CO;2-X.
  • DOI: 10.1002/1529-0131(199912)42
  • Di Sabatino A, Santilli F, Guerci M, et al. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment. Thromb Haemost. 2016;116(3):486-495.
  • DOI: 10.1160/TH16-02-0167
  • Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost. 1998;79:691-705. PMID:
  • ISBN: 9569176
  • Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
  • DOI: 10.1001/jama.286.8.954
  • McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296(13):1633-1644.
  • DOI: 10.1001/jama.296.13.jrv60011
  • Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
  • DOI: 10.1136/bmj.332.7553.1302
  • Bhatt DL. NSAIDS and the risk of myocardial infarction: do they help or harm? Eur Heart J. 2006; 27(14):1635-1636.
  • DOI: 10.1093/eurheartj/ehl090
  • Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA. 2007;297(18):2018-2024.
  • DOI: 10.1001/jama.297.18.2018
  • Santilli F, Guagnano MT, Innocenti P, et al. Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. Circ J. 2016;80(2):502-511.
  • DOI: 10.1253/circj.CJ-15-0721
  • McCullough PA, Vasudevan A, Sathyamoorthy M, et al. Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease. Am J Cardiol. 2017;119(7):972-977.
  • DOI: 10.1016/j.amjcard.2016.12.004
  • Szczeklik W, Stodółkiewicz E, Rzeszutko M, et al. Urinary 11-Dehydro-Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study. J Am Heart Assoc. 2016;5(8):e003702.
  • DOI: 10.1161/JAHA.116.003702
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp